Eli Lilly's Tirzepatide (Mounjaro) Approved for Weight Management and Type 2 Diabetes in Hong Kong
Key Insights
Eli Lilly has received approval to launch its tirzepatide injections, branded as Mounjaro, in Hong Kong.
Mounjaro will be available in a Kwikpen device for both long-term weight management and type 2 diabetes (search) treatment.
Eli Lilly anticipates commencing sales of Mounjaro in Hong Kong as early as the end of this year.
Eli Lilly has secured approval from the Hong Kong government to market its tirzepatide injections, known commercially as Mounjaro, for both long-term weight management and the treatment of type 2 diabetes (search). The company plans to make the drug available in a user-friendly Kwikpen device, potentially launching sales as early as the end of this year, according to a statement released to Bloomberg News.
The approval marks a significant step for individuals in Hong Kong seeking pharmaceutical intervention for weight management and diabetes control. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated notable efficacy in clinical trials for both indications. The Kwikpen delivery system aims to provide a convenient and accessible option for patients.
Details regarding pricing and specific launch dates are expected to be released closer to the commercial availability of Mounjaro in Hong Kong.